Table 1.

Key differences between TROPIC and COU-AA-301 trials³,⁴

Trial parameter	TROPIC	COU-AA-301	Comment
Comparator	Mitoxantrone	Placebo	Mitoxantrone is an active agent, used in mCRPC for symptom palliation2
Geographical range	North America, South America, Australia, Europe, Asia, Africa	North America, Australia, Europe	Inclusion of less developed countries brings potential for wide variation in patient care
Definition of disease progression	Evidence of PSA progression OR radiological progression OR symptomatic progression	Composite of PSA, radiological AND symptomatic progression	Potential that some TROPIC patients were responding to treatment when taken off study

mCRPC: metastatic castration-resistant prostate cancer; PSA: prostate-specific antigen.